Table 3 Cancer Gene Therapy Clinical Trials conducted at HFH using HFH developed vectors

11,253

4809

CD/TKrep-ADP

1 × 10¹²

Arm1: GT + IMRT 80 Gy, Arm2: IMRT 80 Gy

Prostate

44

II

Closed

11/23/21

11,253

2800

CD/TKrep-ADP

1 × 10¹¹ 1 × 10¹²

GT + IMRT 74 Gy

Prostate

9

I

Closed, 10/14/14

16,536

9829

CD/TKrep-IL-12

1 × 10¹⁰ 3 × 10¹⁰ 1 × 10¹¹ 3 × 10¹¹

1 × 10¹²

GT only

Prostate

15

I

Open*

16,536

11,260

CD/TK-rep-IL-12

1 × 10¹¹ 3 × 10¹¹

1 × 10¹²

GT + Chemo

Pancreas

12

I

Completed

12,786

3828

CD/TKrep-hNIS

1 × 10¹¹ 1 × 10¹²

GT + IMRT 76 Gy

Prostate

19

I

Closed, 3/11/14

8436

361

CD/TKrep

1 × 10¹⁰

1 × 10¹¹

1 × 10¹²

GT only

Prostate

16

I

Closed, 6/25/12

9852

588

CD/TKrep

1 × 10¹²

GT + EBRT 70–74 Gy

Prostate

15

I

Closed, 3/11/14

11,253

15,295

CD/TKrep-ADP

1 × 10¹¹ 3 × 10¹¹ 1 × 10¹²

GT + SRS (8 Gy*3)

Glioma

9–18

I

Open/recruiting